Tag Archives: PD-L1

Engineered extracellular vesicles carrying PD-L1 and miR-27a-3p restore T cell balance in IBD models, reducing inflammation while preserving epithelial integrity in inflamed intestinal tissue...

Tumors use extracellular vesicles to export immunosuppressive PD-L1, limiting immunotherapy response, while statins emerge as a practical way...

Engineered extracellular vesicles deliver dual immune targeting to lung metastases, activating T cells and overcoming resistance to checkpoint...

Extracellular vesicles carrying PD-L1 in follicular fluid may regulate immune tolerance and serve as potential biomarkers for fertility assessment and...

Aethlon Medical reported early findings from its Australian oncology trial showing directional changes in extracellular vesicles, exosomes, microRNAs, and lymphocyte counts following Hemopurifier treatment in patients resistant to anti-PD-1 therapy...

Breast cancer is one of the most common cancers worldwide, and detecting it early is crucial for better treatment planning and improving patient outcomes. Researchers at the Beijing Institute of Technology...

Discovery May Help Explain Immunotherapy Resistance, Hints at New Therapies Immunotherapy drugs known as checkpoint inhibitors have revolutionized cancer treatment: many patients with malignancies that until recently would have been considered untreatable are experiencing long-term remissions. But the majority of ...

In order for cancer cells to successfully spread and multiply, they must find a way to avoid the body’s own immune system. Scientists at the German Cancer Research Center (DKFZ) have published an explanation for how this occurs with chronic ...